Rapid Micro Biosystems2022-03-16T14:48:39+00:00

Project Description

Robert Spignesi

Diagnostics & Life Sciences

Boston, Massachusetts, US

Investment Stage

Investment status

Year invested

Endeavour Vision Deal Team
Alexander Schmitz
Rob Barmann
Robert O’Holla

Back to all companies

Rapid Micro Biosystems

Rapid Micro Biosystem’s innovative Growth Direct System® platform is the only system to automate the compendial method of microbial quality control (QC) in the manufacture of healthcare products. The Growth Direct System fully automates traditional microbial testing – detects contamination more quickly, delivering compelling economic benefits, while improving quality control processes and data integrity.

The company completed its initial public offering in July, 2021, and is registered under the ticker Nasdaq:RPID.

Read More

Learn More

Biopharmaceutical manufacturing: Speed, capacity and quality

Contributing towards the clean facility of the future

Alexander Schmitz

Endeavour Vision
Board Member
Alexander Schmitz

Go to Top